The nice people
at “Transfusion News” sent their update today. Perhaps not as useful as some of
their output… but all good stuff.
Genomic Profiles Associated with CAR T-Cell Therapy Efficacy |
 May 24, 2022
Chimeric
antigen receptor (CAR) T-cell therapy is a promising therapy used to
treat hematological cancers by targeting a specific antigen. Notably,
CD19 CAR T-cell therapy has a 90% complete response rate in children and
adults with acute lymphoblastic leukemia (ALL), but it is unclear why
about 10% of patients do not respond to treatment. [Read More]
|
|
|
New perspectives in Transfusion Medicine in Spanish Speaking Countries |
 Join
Transfusion News Associate Editors Daniela Hermelin MD and Monica
Pagano MD on Friday May 27 from 11:00-11:30 AM EST for the next
#Blooducation Baristas live event. Dr. Heremlin and Dr. Pagano will be
joined by Dr. José Arnulfo Pérez-Carrillo, Dra. Silvina Kuperman and Dr.
Hector Baptista for our first event en español. [Set a reminder to join us]
|
|
Risk Factors for Allergic Transfusion Reactions in Pediatric Patients |
 May 17, 2022
Allergic
transfusion reactions (ATRs) are common and can range from mild to
severe. Younger age, hematological/oncological disease, increasing
number of transfusions, and past history of ATRs are all risk factors
for ATRs. Although the exact mechanism for ATRs is not well understood,
type I immunoglobulin E (IgE)-mediated hypersensitivity and/or basophils
are likely involved. [Read More]
|
No comments:
Post a Comment